studies

mBC - TNBC - L2 - PDL1 positive, pembrolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] 0.83[0.70; 0.99]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] 1.28[1.07; 1.54]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] 1.58[0.95; 2.64]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:38 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 240 - treatments: 359,575,577,576,869